Interview with Dr. Girard Deciphers at ELCC 2023

Interview with Dr. Girard Deciphers at ELCC 2023

2024.01.17
The 2023 European Lung Cancer Congress (ELCC) was held from March 29th to April 1st, in a combined online and offline format in Copenhagen, Denmark. Professor Nicolas Girard from the Curie Institute in Paris, France, presented the 3-year data update (Abstract 84O) of the CheckMate 816 study on neoadjuvant immune combined with chemotherapy in the Proffered Paper 2 session. In an interview with Oncology Frontier he further discussed the significant research data released at ELCC 2023, the status of dual immune checkpoint inhibitor regimens in the treatment of driver gene-negative non-small cell lung cancer (NSCLC), and the treatment of EGFR exon 20 insertion mutations (ex20ins) subtype.
Dr. Huibiao Zhang: Three Osimertinib  Adjuvant Studies Shine at ELCC, Adding New Evidence for Early-Stage Lung Cancer Treatment

Dr. Huibiao Zhang: Three Osimertinib  Adjuvant Studies Shine at ELCC, Adding New Evidence for Early-Stage Lung Cancer Treatment

2024.01.17
The European Lung Cancer Congress (ELCC) is one of the most anticipated academic conferences in the field of lung cancer, jointly organized by the European Society for Medical Oncology (ESMO) and the International Association for the Study of Lung Cancer (IASLC). Since its inception in 2008, ELCC has become one of the premier conferences for professionals in this field. The 2023 European Lung Cancer Congress (ELCC) took place in Copenhagen, Denmark, from March 29 to April 1. This conference featured five abstracts on osimertinib, including three adjuvant treatment studies. This article summarizes the latest research results and invites Professor Zhang Huibiao from Fudan University-affiliated Huadong Hospital to provide expert commentary from the perspective of thoracic surgery.
Dr. P. Garrido Lopez Interprets Latest Data from CHRYSALIS

Dr. P. Garrido Lopez Interprets Latest Data from CHRYSALIS

2024.01.17
On the first day of the 2023 European Lung Cancer Congress (ELCC), during the oral presentation session, Dr. P. Garrido Lopez from Ramón y Cajal University Hospital in Madrid, Spain, presented the long-term efficacy, safety, and predictive factors of amivantamab in the treatment of platinum-treated EGFR exon 20 insertion (EGFR ex20ins) mutant advanced non-small cell lung cancer (NSCLC) patients in the CHRYSALIS trial (Abstract No. 3O). In an interview with "Tumor Insight," P. Garrido Lopez further elucidated the results of the CHRYSALIS trial and its clinical significance.
Dr. Zhengfei Zhu: Can EGFR-TKI Combined with Local Consolidative Therapy Achieve “1+1＞2”?

Dr. Zhengfei Zhu: Can EGFR-TKI Combined with Local Consolidative Therapy Achieve “1+1＞2”?

2024.01.15
The 2023 European Lung Cancer Congress (ELCC) is taking place in Copenhagen, the capital of the fairy tale kingdom of Denmark. On the first day of the conference, a session of oral presentations showcased the Phase II randomized study data on EGFR-TKI combined with local consolidative therapy for treating EGFR mutant metastatic non-small cell lung cancer (NSCLC) . Dr.  Zhengfei Zhu from Fudan University Affiliated Tumor Hospital provides commentary on these research findings.
Interview with Dr. Girard Deciphers at ELCC 2023

Interview with Dr. Girard Deciphers at ELCC 2023

2023.10.24
The 2023 European Lung Cancer Congress (ELCC) was held from March 29th to April 1st, in a combined online and offline format in Copenhagen, Denmark. Professor Nicolas Girard from the Curie Institute in Paris, France, presented the 3-year data update (Abstract 84O) of the CheckMate 816 study on neoadjuvant immune combined with chemotherapy in the Proffered Paper 2 session. In an interview with Oncology Frontier he further discussed the significant research data released at ELCC 2023, the status of dual immune checkpoint inhibitor regimens in the treatment of driver gene-negative non-small cell lung cancer (NSCLC), and the treatment of EGFR exon 20 insertion mutations (ex20ins) subtype.
Dr. Huibiao Zhang: ThreeOsimertinib  Adjuvant Studies Shine at ELCC, Adding New Evidence for Early-Stage Lung Cancer Treatment

Dr. Huibiao Zhang: ThreeOsimertinib  Adjuvant Studies Shine at ELCC, Adding New Evidence for Early-Stage Lung Cancer Treatment

2023.10.12
The 2023 European Lung Cancer Congress (ELCC) was held from March 29th to April 1st, in a combined online and offline format in Copenhagen, Denmark. Professor Nicolas Girard from the Curie Institute in Paris, France, presented the 3-year data update (Abstract 84O) of the CheckMate 816 study on neoadjuvant immune combined with chemotherapy in the Proffered Paper 2 session. In an interview with Oncology Frontier he further discussed the significant research data released at ELCC 2023, the status of dual immune checkpoint inhibitor regimens in the treatment of driver gene-negative non-small cell lung cancer (NSCLC), and the treatment of EGFR exon 20 insertion mutations (ex20ins) subtype.
Dr. Zhengfei Zhu: Can EGFR-TKI Combined with Local Consolidative Therapy Achieve “1+1＞2”?

Dr. Zhengfei Zhu: Can EGFR-TKI Combined with Local Consolidative Therapy Achieve “1+1＞2”?

2023.10.12
The 2023 European Lung Cancer Congress (ELCC) is taking place in Copenhagen, the capital of the fairy tale kingdom of Denmark. On the first day of the conference, a session of oral presentations showcased the Phase II randomized study data on EGFR-TKI combined with local consolidative therapy for treating EGFR mutant metastatic non-small cell lung cancer (NSCLC) . Dr.  Zhengfei Zhu from Fudan University Affiliated Tumor Hospital provides commentary on these research findings.
Interview with Dr. Andreas Rimner: The Role of Radiotherapy in the Treatment of Stage III Thymoma

Interview with Dr. Andreas Rimner: The Role of Radiotherapy in the Treatment of Stage III Thymoma

2023.10.12
Thymoma is one of the most common primary tumors in the anterior mediastinum, representing a group of diseases originating from different thymic epithelial cells, characterized by unique clinical and pathological features, often accompanied by various paraneoplastic syndromes. During the "Multidisciplinary Oncology Committee" session held at the 2023 European Lung Cancer Congress (ELCC), several experts discussed the treatment strategies for Stage III thymoma based on a case study. Dr. Andreas Rimner from Memorial Sloan Kettering Cancer Center presented on "The Timing of Radiotherapy in the Treatment of Stage III Thymoma." In an interview with Oncology Frontier, Andreas Rimner shares insights into the role of radiotherapy in the treatment of Stage III thymoma.
Interview with Dr. Martin Reck at ELCC 2023

Interview with Dr. Martin Reck at ELCC 2023

2023.10.12
The 2023 European Lung Cancer Congress (ELCC) recently concluded in Copenhagen. In an interview with Oncology Frontier, 2023 ELCC Scientific Co-Chairs Professor Martin Reck reviewed the most significant oral presentations of the conference and shared insights on the selection of first-line immunotherapy regimens.
Dr. P. Garrido Lopez Interprets Latest Data from CHRYSALIS

Dr. P. Garrido Lopez Interprets Latest Data from CHRYSALIS

2023.10.12
On the first day of the 2023 European Lung Cancer Congress (ELCC), during the oral presentation session, Dr. P. Garrido Lopez from Ramón y Cajal University Hospital in Madrid, Spain, presented the long-term efficacy, safety, and predictive factors of amivantamab in the treatment of platinum-treated EGFR exon 20 insertion (EGFR ex20ins) mutant advanced non-small cell lung cancer (NSCLC) patients in the CHRYSALIS trial (Abstract No. 3O). In an interview with "Tumor Insight," P. Garrido Lopez further elucidated the results of the CHRYSALIS trial and its clinical significance.